Share on StockTwits

Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Howard Lee acquired 6,000 shares of Amphastar Pharmaceuticals stock on the open market in a transaction dated Monday, August 25th. The stock was purchased at an average cost of $10.84 per share, with a total value of $65,040.00. Following the completion of the acquisition, the director now directly owns 101,215 shares in the company, valued at approximately $1,097,171. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of analysts have recently weighed in on AMPH shares. Analysts at Jefferies Group raised their price target on shares of Amphastar Pharmaceuticals from $14.00 to $15.00 in a research note on Wednesday, August 13th. They now have a “buy” rating on the stock. Separately, analysts at BMO Capital Markets raised their price target on shares of Amphastar Pharmaceuticals from $17.00 to $18.00 in a research note on Wednesday, August 6th. Finally, analysts at Needham & Company LLC initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $17.00 price target on the stock.

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) traded down 1.22% on Wednesday, hitting $11.36. 107,785 shares of the company’s stock traded hands. Amphastar Pharmaceuticals has a one year low of $6.67 and a one year high of $12.18. The stock’s 50-day moving average is $9.59 and its 200-day moving average is $9.57. The company’s market cap is $507.2 million.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings data on Tuesday, August 12th. The company reported $0.02 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.11) by $0.13. Analysts expect that Amphastar Pharmaceuticals will post $-0.17 EPS for the current fiscal year.

Amphastar Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.